All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Breakthrough therapy designation granted to revumenib by the FDA

Dec 7, 2022
Learning objective: After reading this update, learners will be able to cite a new development in the treatment of AML.

Bookmark this article

On December 5, 2022, revumenib, a potent, selective, small molecule inhibitor of the menin-mixed lineage leukemia (MLL) binding interaction, was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients with relapsed/refractory acute leukemia, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), with KMT2A rearrangements.1

This designation is based on data from the phase I part of the AUGMENT-101 trial (NCT04065399). The study design and initial data and additional results from the AUGMENT-101 trial have previously been covered by the AML Hub. Briefly, patients with ALL or AML and KMT2A rearrangements and patients with NPM1-mutated AML were included in the trial. At the March 2022 data cutoff, the rate of complete remission or complete remission with partial hematological recovery was 27% for patients with KMT2A rearranged-acute leukemia who received the recommended phase II dose. No patients discontinued treatment due to treatment-related adverse events.1

Revumenib continues to be investigated in several trials, including the phase II part of the AUGMENT-101 trial.

  1.  Syndax announces U.S. FDA breakthrough therapy designation granted for revumenib for the treatment of adult and pediatric patients with relapsed or refractory KMT2A- rearranged (MLLr) acute leukemia. Published Dec 5, 2022. Accessed Dec 6, 2022.


Subscribe to get the best content related to AML delivered to your inbox